Experts push compulsory licensing review for cancer drug prices
In short
Public health advocates said the government should check whether cancer drugs are truly affordable, not just count how many brands cut prices. They also want tighter checks on pharma pricing.
The concern is that lower list prices may not mean patients can afford treatment. The report does not name any drug or say the government has acted yet.
What the reporting says
Public health advocates called on the government to assess affordability instead of relying only on the number of brands reporting price cuts for cancer drugs. Their argument appears aimed at tighter checks on pharma pricing and possible use of compulsory licensing. The source does not name specific medicines, companies, or any policy decision already taken.
Why it matters
Public health advocates said the government should assess affordability rather than rely only on the number of brands reporting price cuts for cancer drugs. The comments point to pressure for tighter pricing checks and possibly compulsory licensing. The reporting does not name any medicine, company, or policy response, so the immediate outcome is still unknown.